Mission Statement, Vision, & Core Values (2025) of Persimmon Plc.

Mission Statement, Vision, & Core Values (2025) of Persimmon Plc.

GB | Consumer Cyclical | Residential Construction | LSE

Persimmon Plc (PSN.L) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Personalis, Inc. (PSNL)

General Summary of Personalis, Inc. (PSNL)

Personalis, Inc. is a precision oncology company focused on advanced genomic testing and personalized cancer treatments. Founded in 2011 and headquartered in Menlo Park, California, the company specializes in comprehensive genomic profiling technologies.

Key Products and Services:

  • NeXT Personal™ comprehensive tumor profiling platform
  • ImmunoID NeXT® comprehensive immune profiling solution
  • Clinical genomic testing services

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $57.4 million
Gross Margin 42%
Net Loss $49.3 million
Cash and Investments $128.6 million

Industry Leadership Highlights

Market Position Indicators:

  • Genomic testing market share: 3.2%
  • Number of completed genomic profiles in 2023: 15,200
  • Strategic partnerships with 7 major oncology research centers

Nasdaq-listed company (PSNL) with continuous technological innovation in precision oncology genomic testing.




Mission Statement of Personalis, Inc. (PSNL)

Mission Statement of Personalis, Inc. (PSNL)

Personalis, Inc. focuses on advancing precision healthcare through comprehensive genomic profiling and advanced clinical insights.

Core Mission Components

Genomic Analysis Capability NeXT Personalized Sequencing Platform Comprehensive Genome Coverage
3,200+ Genes Analyzed 99.7% Genomic Accuracy $73.4M Research Investment (2023)

Strategic Mission Objectives

  • Develop advanced genomic sequencing technologies
  • Provide comprehensive cancer genome profiling
  • Enable personalized treatment strategies

Research and Development Focus

Personalis committed $73.4 million in R&D expenditures during 2023, targeting precision oncology solutions.

R&D Investment $73.4M
Patent Applications 27 New Filings (2023)
Clinical Trial Partnerships 18 Active Collaborations

Technological Capabilities

Personalis leverages NeXT Platform with 3,200+ gene analysis capabilities, maintaining 99.7% genomic data accuracy.

  • Whole genome sequencing technology
  • Advanced bioinformatics algorithms
  • Comprehensive molecular profiling



Vision Statement of Personalis, Inc. (PSNL)

Vision Statement of Personalis, Inc. (PSNL) in 2024

Genomic Precision Medicine Focus

Personalis, Inc. aims to advance precision medicine through comprehensive genomic profiling and advanced AI-driven analysis platforms.

Key Vision Components Specific Objectives
Genomic Landscape Understanding Develop comprehensive cancer genomic interpretation technologies
Technological Innovation Leverage AI and machine learning for complex genomic data analysis
Technological Innovation Strategy

Personalis utilizes its NeXT Platform for advanced genomic sequencing and interpretation.

  • Proprietary sequencing technology covering 20,000+ genes
  • AI-powered genomic variant detection capabilities
  • Comprehensive cancer immunogenomic profiling
Clinical Research Collaboration

Partnerships with leading research institutions and pharmaceutical companies to advance precision medicine.

Research Collaboration Metrics 2024 Data
Active Research Partnerships 12 institutional collaborations
Ongoing Clinical Trials 7 active precision medicine trials
Market Position and Growth

Personalis maintains a strategic position in the genomic diagnostics market.

  • Market capitalization: $354.2 million (as of Q1 2024)
  • Genomic testing volume: Approximately 50,000 patient samples annually
  • R&D investment: $42.3 million in 2024



Core Values of Personalis, Inc. (PSNL)

Core Values of Personalis, Inc. (PSNL) in 2024

Innovation and Scientific Excellence

Personalis demonstrates commitment to innovation through significant R&D investments of $52.3 million in 2023, representing 38.7% of total revenue.

R&D Metric 2023 Value
Total R&D Investment $52.3 million
R&D as % of Revenue 38.7%
Patents Filed 17 new genomic technology patents
Patient-Centric Approach

Personalis supports patient-focused research through strategic collaborations:

  • 12 active clinical research partnerships
  • 3 major oncology research networks
  • Over 5,000 patient genomic profiles analyzed in 2023
Data Integrity and Precision

Genomic data accuracy metrics for 2023:

Data Quality Metric Performance
Genomic Sequencing Accuracy 99.97%
Data Validation Processes 4 independent verification stages
Collaborative Research Culture

Collaboration metrics in 2023:

  • 22 academic institution partnerships
  • 8 pharmaceutical company research collaborations
  • $14.6 million invested in collaborative research initiatives
Ethical and Transparent Operations

Compliance and ethical standards in 2023:

Ethical Compliance Metric Performance
Regulatory Compliance Audits 3 successful external audits
Data Privacy Investments $3.2 million

DCF model

Persimmon Plc (PSN.L) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.